NMB's musc/rheum Flashcards
NON-depol-ISOQUINOLONE DERIVATIVES
ATRACURIUM
CISATRICURIUM
(D-TUBOCURARINE NOT USED)
NON-depol-STEROID DERIVATIVES
PANCURONIUM
ROCURONIUM
VECURONIUM
DEPOLARIZATING AGENT
SUCCINYLCHOLINE
REVERSAL AGENTS
EDROPHONIUM
PYROSTIGIMINE
NEOSTIGIMINE
SUGGAMEDEX–> FOR STEROID AGENTS ONLY
WHERE all are muscarinic receptors found
Nm= neuromuscular end plate in skeletal muscle
Nn=autonomic ganglia
where all are muscarinic receptors found
Nerves, Heart and smooth muscle, gland and epithelium
action of paralytics
Nm receptor blockade (hopefully wit no Nn blockade…but obvi, not possible)
where is the ryanodine receptor located
sarcoplasmic triad and controls the release of Ca2+
depolarization and phase II blockade
succinyl choline and pancuronium
what type of channel in Nm receptor
multi-subunit, ligand gates ion (Na+) channel
–> takes TWO ach molecules for activation
blockade of mucle contraction
dantrolene
reversals that inhibit ACHE accomplish what
allow Ach to linger in the cleft…more time to generate an AP..reversal of Nm inhibition
fundamental different between non-depol and depol agents
ROCURONIUM: non-depols prevent ANY activation of muscle contraction
SUCC CHOL: depols- gates for initial muscle contraction but persisists on the receptor, disallowing reconfiguration and repoening…therfore flaccid paralysis ensues because the OPEN Na channel is physically blocked by another molecule of the drug
DESCRIBE FADE
TOF TECHNIQUE: WHEN NON-DEPOLARIZING DRUGS OCCUPYING NEUROMUSCULAR BLOCKERS–> the strength of the fourth twitch is less than the first until eventually the muscle does not twitch with the 4th stim
(normally the first and the fourth ar equal intensity w/o blockade)
titration of doses of NMB’s in the ICU is
typically two or three of four trwitches are sought (usually this takes place at around 70-85% of the receptors being occupied)…
Define PTP
Post tetanic potentiation seen in sustained stimulation peripheral nerve stimulation
- -> represents synaptic palsticity caused by Ca dependent activation of PKC…increases the # of release Ach vesicles (quantal content) by increasing release probablity and o the readily released pool size
- increasing the release quantal content…is able to out-compete, briefly< witht eh NMBloackade with Non-depols and in phase II with succ
which drugs exhibit clean fade
NON-depols
Succinyl CHoline in the TOF phase I
phase 1–> no fade…constant but diminished
succinyl choline in the TOF phase II
fade
AchE inhibition in phase one
augments
AchE inhibition in phase II
reverses or antagonizes
muscle response in phase I
fasciculations nd then paralysis
muscle response in Phase II
flaccid paralysis
NON-depol metabolic fate
duration of action correlates with I/2 life
which eleiminiation of steroidal NonDep is quicker
hepatic is quicker than renal